Athira Pharma Inc

For the period ended Mar 31, 2025. Filed May 9, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 9, 2025

LONA$4.02-10.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

(in thousands)

	Three Months Ended March 31,
	2025	2024
Operating activities
Net loss	$(9,143)	$(26,337)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	1,637	2,679
Depreciation expense	243	242
Non-cash lease expense	65	57
Amortization of premiums and accretion of discounts on available-for-sale securities, net	(65)	(266)
Loss on disposal of equipment	—	7
Changes in operating assets and liabilities:
Prepaid expenses and other current and long-term assets, net	353	1,155
Accounts payable and accrued liabilities	(7,655)	(3,254)
Operating lease liability	(100)	(87)
Net cash used in operating activities	(14,665)	(25,804)
Investing activities
Purchases of available-for-sale securities	(10,201)	(5,911)
Maturities of available-for-sale securities	2,850	18,957
Purchases of property and equipment	—	(5)
Net cash (used in) provided by investing activities	(7,351)	13,041
Financing activities
Net cash provided by financing activities	—	—
Net decrease in cash, cash equivalents and restricted cash	(22,016)	(12,763)
Cash, cash equivalents and restricted cash, beginning of period	49,069	91,215
Cash, cash equivalents and restricted cash, end of period	$27,053	$78,452

ATHIRA PHARMA, INC.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.